Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens.
To develop a CELO virus vector that can induce protection against infectious bursal disease, CELO viruses expressing the host-protective antigen VP2 of infectious bursal disease virus (IBDV) were constructed. In the engineered recombinants, the VP2 gene (the 441-first codons of the IBDA polyprotein) was placed under the control of the CMV promoter. Two positions in the CELO genome were chosen to insert the VP2 expression cassette. The recombinants were found apathogenic, when inoculated by different routes and even at high doses (up to 10(8) per animal). Chickens vaccinated oro-nasally with these different recombinants and challenged with very virulent IBDV were found to be poorly protected. In contrast, when inoculated with one or two (subcutaneous or intradermic) injections of CELOa-VP2, the chickens showed no clinical signs and no mortality after challenge. In the vaccinated chickens, the titers of neutralization antibody reached 7-9 values, showing that protection could be explained by the induction of a sufficient humoral response. After challenge, the weight ratio Bursa of Fabricius/body was about 2.5 per thousand, a value similar to that obtained with the commercial Bur706 vaccine. However, histological lesions in the Bursa of Fabricius were observed, showing that a complete protection was not totally achieved. Contact transmission was evidenced. Protection was also obtained when inoculation of CELOa-VP2 was carried out in ovo. Prime-boost strategies were also tested with the CELOa-VP2 vector used in association with the purified VP2 antigen, or DNA encoding VP2 or a CELO vector expressing chicken myeloid growth factor (cMGF). None of these regimens were shown to substantially increase the level of protection when compared to double CELOa-VP2 inoculations. These results indicate that CELO-based vectors are useful to safely induce a strong protective immunity against vvIBDV in chickens.
Francois
Achille
A
Agence Française de Sécurité Sanitaire des Aliments, Molecular Biology Unit, Zoopôle Les Croix, B.P. 53, Ploufragan 22440, France.
Chevalier
Christophe
C
Delmas
Bernard
B
Eterradossi
Nicolas
N
Toquin
Didier
D
Rivallan
Gaëlle
G
Langlois
Patrick
P
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018175:Birnaviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D002060:Bursa of Fabricius / Q000473:pathology; D002645:Chickens; D025681:Fowl adenovirus A / Q000235:genetics* / Q000276:immunology; D015967:Gene Expression Regulation, Viral; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007243:Infectious bursal disease virus / Q000276:immunology*; D009500:Neutralization Tests; D011201:Poultry Diseases / Q000517:prevention & control*; D011401:Promoter Regions, Genetic; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; C082513:VP2 protein, infectious bursal disease virus; D014614:Vaccines, Synthetic; D015678:Viral Structural Proteins; D014765:Viral Vaccines